Abstract
Cardiovascular disease (CVD) is the leading cause of death in patients with type 2 diabetes. Epidemiological studies have shown that diabetes mellitus is a potent independent risk factor for cardiovascular disease.1, 2 It has been recognized for several decades that diabetic patients have a 2 to 3 fold higher risk for CVD than their nondiabetic counterparts. CVD accounts for up to 80% of deaths in patients with diabetes, approximately 75% of which are due to ischemic heart disease. More than 25% of diabetic patients have evidence of CVD at diagnosis. Therefore, the American Heart Association has stated that “diabetes is a cardiovascular disease”.3
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Garcia MJ, McNamara M, Gordon T, Kannel WB. 16 year follow-up study. Morbidity and mortality in diabetics in the Framingham population. Diabetes 23: 105, 1976.
Kannel WB, McGee DL. Diabetes and Cardiovascular disease; the Framingham Study. JAMA 241: 2035–8, 1979.
Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (10): 1134–46, 1999.
Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 5: 294–315, 1997.
Brezinka V, Padmos I. Coronary heart disease risk factors in women. Eur Heart J 15: 1571–1584, 1994.
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (4): 229–34, 1998.
Stone PH, Muller JE, Hartwell, T, et al. The MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary artery disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol 14: 49–57, 1989.
Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 281: 1291–1297, 1999.
Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 21: 69–75, 1998.
Naka M, Hiramatsu K, Aizawa T, et al. Silent myocardial ischemia in non-insulin dependent diabetes as judged by treadmill exercise testing and coronary angiography. Am Heart J 123: 46–52, 1992.
Langer A, Freeman M, Josse R, et al. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 67: 1073–8, 1991.
Caracciolo EA, Chaitman BR, Forman SR et al. Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of non-diabetic patients. Circulation 1996; 93: 2097–2105.
Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial (MRFIT). Diabetes Care 16: 434–444, 1993.
ADA Consensus Panel. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes: American Diabetes Association. Diabetes Care 12: 573–579, 1989.
Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helskinki Heart Study. Diabetes Care15(7): 820–5, 1992.
Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (4): 614–20, 1997.
Goldberg RB, Mellies MJ, Sacks FM et al. For the CARE investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 98: 2513–2519, 1998.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–2497, 2001.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 351 (9118): 1755–62, 1998.
Curb JD, Pressel SL, Cutler JA, et al. for the Systolic Hypertension in the Elderly Program Cooperative Research Group: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276: 1886–1892, 1996.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317 (7160): 703–13, 1998.
Estacio RO, Jeffers BW, Hiatt WR et al: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 338: 645–652, 1998.
Tatti P, Pahor M, Byrington RB, et al: Outcome results of the Fosinopril Versus Amlopidine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21: 597–603, 1998.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetees mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355:253–9, 2000.
Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356–360, 1994.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001.
Brownlee M. Glycation and diabetic complications. Diabetes 43: 83641, 1994.
West KM, Ahuja MM, Bennet PH, et al. The role of circulating glucose and triglyceride concentrations and their interactions with other “risk factors” as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care 6: 361–369, 1983.
Wilson WF, Cupples AD, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 2: 586–590, 1991.
Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: Putative association via common antecedents: Further evidence from the Whitehall Study. Diabetologia 31:737–740, 1988.
Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43: 960–967, 1994.
Klein R: Kelly West Lecture 1994: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care18: 258–268, 1995.
Diabetes Control and Complications Trial Research Group (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986, 1993.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352: 837–852, 1998.
Colwell JA: Aspirin therapy in diabetes. Diabetes Care 20: 1767–1771, 1997.
Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 26: 57–65, 1995.
KendallMJ, Lynch KP, Hjalmarson A, et al. Beta-blockers and sudden cardiac death. Ann Intern Med 123: 358–67, 1995.
Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimai hyperplasia. Circulation 95: 1366–69, 1997.
The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335: 217–25, 1996.
King SB, Lembo NJ, Weintraub WS, et al, for the Emory Angioplasty Versus Surgery Trial (EAST). A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med 331: 1044–50, 1994.
Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs. women. The Framingham Study. JAMA 260: 3456, 1988.
Liu JE, Robbins DC, Sosenko J, et al. Abnormal LV Structure and Function are Associated with Recent Conversion from Normal Glucose Tolerance to Diabetes Mellitus — the Strong Heart Study (SHS). Diabetes Supp12: 50: 147, 2001.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561–1566, 1990.
Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 273: 1592–1597, 1995.
Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Cardiovascular Drugs Ther 8: 65–73, 1994.
Van Hoeven KV, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 82: 848–855, 1990.
Galderisi M, Anderson KM, Wilson PW et al. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am J Cardiol 68: 85–89, 1991.
Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function. The Strong Heart Study Circulation 101: 2271–2276, 2000.
Bella JN, Devereux RB, Roman MJ, et al. Separate and joint cardiovascular effects of hypertension and diabetes: The Strong Heart Study. Am J Cardiol 87: 1260–5, 2001.
Liu JE, Palmieri V, Roman MJ et al. Cardiovascular disease and prognosis in adults with glucose disorders: The Strong Heart Study. J Am Coll Cardiol 35: 263A, 2000.
Regan TJ, Wu CF, Yeh CK, Oldewurtle HA, Haider B. Myocardial composition and function in diabetes: the effect of chronic insulin use. Circ Res 49: 1268–1277, 1981.
Jain A, Avendano G, Dharamsey S, et al. Left ventricular diastolic function in hypertension and role of plasma glucose and insulin. Comparison with diabetic heart. Circulation 93: 1396–1402, 1996.
Mock MB, Ringqvist I, Fischer LD, and Participants in the Coronary Artery Surgery Study (CASS) Registry. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 66: 562–571, 1982.
Liu JE, Palmieri V, Roman MJ, et. al. The impact of glycemia and diabetes on left ventricular filling pattern: The Strong Heart Study. J Am Coll Cardiol 37: 1943–9, 2001.
Bella JN, Palmieri V, Roman MJ, et al. Prognostic significance of abnormal peak early to late diastolic filling ratio in middle-aged to elderly American Indians: The Strong Heart Study. J Am Coll Cardiol 35: 293A, 2000.
Liu, J.E., Palmieri V, Roman MJ, et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: The Strong Heart Study. J Am Coll Cardiol 37: 221A, 2001.
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, KofoedEnevoldsen. Albuminuria reflects widespread vascular damage — The Steno Hypothesis. Diabetologia 32: 219–226, 1989.
Yla-Herrtuala S, Sumuvuori H, Karkola K, Mottonen M, Nikkari T.Glycosaminoglycans in normal and atherosclerotic human coronary arteries. Lab Invest 61: 231–236, 1986.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Liu, J.E., Devereux, R.B. (2004). Coronary Artery Disease and Cardiomyopathy. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6260-0_37
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6260-0_37
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-6262-4
Online ISBN: 978-1-4757-6260-0
eBook Packages: Springer Book Archive